Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Tues 6 June 2017, researchers vaccinated volunteers and began Mahidol University’s study of the malaria vaccine RTS,S/AS01. This is the first study in Asia of the vaccine, an advanced product that has received regulatory approval in Europe.

Researchers with Nick White

On Tues 6 June, researchers vaccinated volunteers and began Mahidol University’s study of the malaria vaccine RTS,S/AS01. This is the first study in Asia of the vaccine, an advanced product that has received regulatory approval in Europe.

Several extensive clinical trials of RTS,S/AS01 have previously been conducted in children in sub-Saharan Africa. In a large Phase 3 trial of RTS,S/AS01E at 11 sites in seven sub-Saharan African countries, efficacy against clinical malaria in children aged 5–17 months following three primary doses was 45.1% (CI 41.4 to 48.7), 35.2% (CI 30.5 to 39.5) and 28.3% (CI 23.3 to 32.9) during 20, 32 and 48 months of follow-up, respectively.

Profs. Sasithon (3rd left), Nick White (centre) and colleagues show their delight that Mahidol’s RTS,S/AS01 vaccine study has started. Right: The RTS,S/AS01 vaccine and adjuvant.

While such a “leaky” vaccine is not ideal in high transmission settings, it could be useful in combination with other interventions such as mass drug administrations in the elimination of malaria in the Greater Mekong Subregion, leading malaria researchers say.

“RTS,S is the most advanced of the malaria vaccine candidates. This is the first time the vaccine is evaluated in an Asian population. If found to be safe and effective, RTS,S could be the urgently needed tool to expedite the elimination of malaria in the Greater Mekong Subregion,” said Dr Lorenz von Seidlein, Coordinator of MORU’s TME programme.

Expected to last 6 months, the Mahidol study will recruit 190 health adult volunteers to explore the immunogenicity and safety of various vaccine regimens with and without antimalarial drugs.

Funded by the Malaria Vaccine Initiative/PATH, the study is supervised by Mahidol Prof Sasithon Pukrittayakamee, Dr Borimas Hanboonkunupakarn and Dr Podjanee Jittamala and is coordinated by Pongphaya Pongsuwan. MORU investigators Sir Nick White, Nick Day, Arjen Dondorp and Lorenz von Seidlein will support the study implementation.

Similar stories

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.